PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
NYSE:MD • US58502B1061
19.725 USD
+0.91 (+4.81%)
Last: Feb 23, 2026, 02:12 PM
Taking everything into account, MD scores 6 out of 10 in our fundamental rating. MD was compared to 101 industry peers in the Health Care Providers & Services industry. While MD belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. MD is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make MD suitable for value investing!
1. Profitability
1.1 Basic Checks
- In the past year MD was profitable.
- In the past year MD had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
- In the past 5 years MD always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of MD (7.36%) is better than 90.10% of its industry peers.
- MD's Return On Equity of 19.10% is amongst the best of the industry. MD outperforms 86.14% of its industry peers.
- With an excellent Return On Invested Capital value of 9.88%, MD belongs to the best of the industry, outperforming 80.20% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for MD is in line with the industry average of 9.04%.
- The 3 year average ROIC (8.21%) for MD is below the current ROIC(9.88%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.36% | ||
| ROE | 19.1% | ||
| ROIC | 9.88% |
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
1.3 Margins
- Looking at the Profit Margin, with a value of 8.64%, MD belongs to the top of the industry, outperforming 91.09% of the companies in the same industry.
- MD's Profit Margin has improved in the last couple of years.
- Looking at the Operating Margin, with a value of 12.07%, MD belongs to the top of the industry, outperforming 83.17% of the companies in the same industry.
- In the last couple of years the Operating Margin of MD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.07% | ||
| PM (TTM) | 8.64% | ||
| GM | N/A |
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MD is creating some value.
- Compared to 1 year ago, MD has less shares outstanding
- Compared to 5 years ago, MD has less shares outstanding
- The debt/assets ratio for MD has been reduced compared to a year ago.
2.2 Solvency
- MD has an Altman-Z score of 2.00. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
- MD's Altman-Z score of 2.00 is in line compared to the rest of the industry. MD outperforms 51.49% of its industry peers.
- The Debt to FCF ratio of MD is 2.36, which is a good value as it means it would take MD, 2.36 years of fcf income to pay off all of its debts.
- With a decent Debt to FCF ratio value of 2.36, MD is doing good in the industry, outperforming 75.25% of the companies in the same industry.
- MD has a Debt/Equity ratio of 0.66. This is a neutral value indicating MD is somewhat dependend on debt financing.
- MD has a Debt to Equity ratio (0.66) which is comparable to the rest of the industry.
- Although MD does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 2.36 | ||
| Altman-Z | 2 |
ROIC/WACC1.2
WACC8.25%
2.3 Liquidity
- MD has a Current Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
- MD's Current ratio of 1.66 is fine compared to the rest of the industry. MD outperforms 65.35% of its industry peers.
- MD has a Quick Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
- MD has a Quick ratio of 1.66. This is in the better half of the industry: MD outperforms 69.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 |
3. Growth
3.1 Past
- MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.24%, which is quite impressive.
- MD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.01% yearly.
- Looking at the last year, MD shows a decrease in Revenue. The Revenue has decreased by -4.92% in the last year.
- The Revenue has been growing slightly by 1.99% on average over the past years.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
3.2 Future
- Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 1.48% on average per year.
- The Revenue is expected to grow by 4.60% on average over the next years.
EPS Next Y10.99%
EPS Next 2Y8.08%
EPS Next 3Y2.62%
EPS Next 5Y1.48%
Revenue Next Year2.7%
Revenue Next 2Y2.49%
Revenue Next 3Y4.56%
Revenue Next 5Y4.6%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 9.72, the valuation of MD can be described as very reasonable.
- 94.06% of the companies in the same industry are more expensive than MD, based on the Price/Earnings ratio.
- MD is valuated cheaply when we compare the Price/Earnings ratio to 26.99, which is the current average of the S&P500 Index.
- With a Price/Forward Earnings ratio of 8.75, the valuation of MD can be described as very reasonable.
- 94.06% of the companies in the same industry are more expensive than MD, based on the Price/Forward Earnings ratio.
- When comparing the Price/Forward Earnings ratio of MD to the average of the S&P500 Index (28.02), we can say MD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.72 | ||
| Fwd PE | 8.75 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MD is valued cheaper than 88.12% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, MD is valued cheaper than 91.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.71 | ||
| EV/EBITDA | 6.28 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of MD may justify a higher PE ratio.
PEG (NY)0.88
PEG (5Y)0.97
EPS Next 2Y8.08%
EPS Next 3Y2.62%
5. Dividend
5.1 Amount
- MD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:MD (2/23/2026, 2:12:07 PM)
19.725
+0.91 (+4.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19 2026-02-19/bmo
Earnings (Next)05-04 2026-05-04/bmo
Inst Owners98.9%
Inst Owner Change0.65%
Ins Owners1.87%
Ins Owner Change-1.02%
Market Cap1.69B
Revenue(TTM)1.91B
Net Income(TTM)165.39M
Analysts78.67
Price Target23.12 (17.21%)
Short Float %3.33%
Short Ratio4.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.87%
Min EPS beat(2)-9.94%
Max EPS beat(2)39.68%
EPS beat(4)3
Avg EPS beat(4)20.9%
Min EPS beat(4)-9.94%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)17.99%
EPS beat(12)7
Avg EPS beat(12)8.59%
EPS beat(16)8
Avg EPS beat(16)5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.49%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)2
Avg Revenue beat(12)-2.28%
Revenue beat(16)2
Avg Revenue beat(16)-2.52%
PT rev (1m)0%
PT rev (3m)35.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3%
EPS NY rev (1m)0%
EPS NY rev (3m)16.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.72 | ||
| Fwd PE | 8.75 | ||
| P/S | 0.89 | ||
| P/FCF | 6.71 | ||
| P/OCF | 6.25 | ||
| P/B | 1.96 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.28 |
EPS(TTM)2.03
EY10.29%
EPS(NY)2.25
Fwd EY11.42%
FCF(TTM)2.94
FCFY14.91%
OCF(TTM)3.16
OCFY16%
SpS22.29
BVpS10.08
TBVpS-4.79
PEG (NY)0.88
PEG (5Y)0.97
Graham Number21.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.36% | ||
| ROE | 19.1% | ||
| ROCE | 12.93% | ||
| ROIC | 9.88% | ||
| ROICexc | 13.71% | ||
| ROICexgc | 1686.9% | ||
| OM | 12.07% | ||
| PM (TTM) | 8.64% | ||
| GM | N/A | ||
| FCFM | 13.2% |
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
ROICexc(3y)10.42%
ROICexc(5y)9.77%
ROICexgc(3y)618.91%
ROICexgc(5y)394.62%
ROCE(3y)10.75%
ROCE(5y)10.43%
ROICexgc growth 3Y208.98%
ROICexgc growth 5Y85.34%
ROICexc growth 3Y17.7%
ROICexc growth 5Y11.82%
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 2.36 | ||
| Debt/EBITDA | 2.26 | ||
| Cap/Depr | 84.57% | ||
| Cap/Sales | 0.96% | ||
| Interest Coverage | 6.72 | ||
| Cash Conversion | 107.19% | ||
| Profit Quality | 152.75% | ||
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 | ||
| Altman-Z | 2 |
F-Score8
WACC8.25%
ROIC/WACC1.2
Cap/Depr(3y)81.68%
Cap/Depr(5y)85.74%
Cap/Sales(3y)1.24%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y10.99%
EPS Next 2Y8.08%
EPS Next 3Y2.62%
EPS Next 5Y1.48%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
Revenue Next Year2.7%
Revenue Next 2Y2.49%
Revenue Next 3Y4.56%
Revenue Next 5Y4.6%
EBIT growth 1Y25.81%
EBIT growth 3Y4.93%
EBIT growth 5Y6.1%
EBIT Next Year15.03%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.89%
FCF growth 3Y22.56%
FCF growth 5Y7.52%
OCF growth 1Y31.23%
OCF growth 3Y17.54%
OCF growth 5Y5.79%
PEDIATRIX MEDICAL GROUP INC / MD FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MD.
What is the valuation status for MD stock?
ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 7 / 10.
What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?
The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 9.72 and the Price/Book (PB) ratio is 1.96.